^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Stivarga (regorafenib) (Multi-tyrosine kinase inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PD-L1 Expression on Circulating Tumour Cells May Be Predictive of Response to Regorafenib in Patients Diagnosed with Chemorefractory Metastatic Colorectal Cancer
Published date:
09/20/2020
Excerpt:
Our study identified a total of 40 consecutive patients, all of them Caucasian, diagnosed with chemorefractory metastatic colorectal cancer. Treated with standard-of-care regorafenib as third-line metastatic therapy...The presence of PD-L1− CTCs was significantly associated with worse PFS (median PFS: 2.1 months, range 1–4 months). The median PFS for PD-L1+ CTCs patients was 6.3 months, range 4–12 months).
DOI:
10.3390/ijms21186907
